"bcl-X Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the bcl-2 protein family that plays a role in the regulation of APOPTOSIS and is a regulatory subunit for PROTEIN PHOSPHATASE 1. Two major isoforms of the protein exist due to ALTERNATIVE SPLICING of the BCL2L1 mRNA and are referred to as Bcl-XS and Bcl-XL.
| Descriptor ID |
D051020
|
| MeSH Number(s) |
D12.644.360.075.718.937 D12.776.476.075.718.875
|
| Concept/Terms |
bcl-X Protein- bcl-X Protein
- bcl X Protein
- bcl2-Like 1 Protein
- bcl2 Like 1 Protein
- bcl2L1 Protein
bcl-XS Protein- bcl-XS Protein
- bcl XS Protein
- bcl-Xshort Protein
- bcl Xshort Protein
- bcl-X(S) Protein
bcl-Xbeta Protein- bcl-Xbeta Protein
- bcl Xbeta Protein
- bcl-Xb Protein
- bcl Xb Protein
- bcl-x(beta) Protein
bcl-XL Protein- bcl-XL Protein
- bcl XL Protein
- bcl-Xlong Protein
- bcl Xlong Protein
- bcl-X(L) Protein
|
Below are MeSH descriptors whose meaning is more general than "bcl-X Protein".
Below are MeSH descriptors whose meaning is more specific than "bcl-X Protein".
This graph shows the total number of publications written about "bcl-X Protein" by people in this website by year, and whether "bcl-X Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 3 | 1 | 4 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2009 | 1 | 3 | 4 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "bcl-X Protein" by people in Profiles.
-
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clin Cancer Res. 2024 May 01; 30(9):1739-1749.
-
Treatment with the BCL-2/BCL-xL inhibitor senolytic drug ABT263/Navitoclax improves functional hyperemia in aged mice. Geroscience. 2021 10; 43(5):2427-2440.
-
Early and delayed intervention with rapamycin prevents NNK-induced lung adenocarcinoma in A/J mice. Oncol Rep. 2015 Dec; 34(6):2925-34.
-
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015 Aug; 14(4):644-58.
-
Physical and functional interaction of the proto-oncogene EVI1 and tumor suppressor gene HIC1 deregulates Bcl-xL mediated block in apoptosis. Int J Biochem Cell Biol. 2014 Aug; 53:320-8.
-
After embedding in membranes antiapoptotic Bcl-XL protein binds both Bcl-2 homology region 3 and helix 1 of proapoptotic Bax protein to inhibit apoptotic mitochondrial permeabilization. J Biol Chem. 2014 Apr 25; 289(17):11873-11896.
-
SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide. Biochim Biophys Acta. 2013 Oct; 1833(10):2357-68.
-
Role of fatty-acid synthesis in dendritic cell generation and function. J Immunol. 2013 May 01; 190(9):4640-9.
-
Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis. PLoS One. 2011; 6(9):e25370.
-
Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis. Gastroenterology. 2010 Feb; 138(2):616-26, 626.e1-2.